| 178 | Pneumonia, Viral |
| 178 | Coronavirus Infections |
| 177 | Pandemics |
| 177 | Humans |
| 145 | Betacoronavirus |
| 81 | Cardiovascular Diseases |
| 48 | Comorbidity |
| 47 | Male |
| 46 | Female |
| 43 | Risk Factors |
| 43 | Aged |
| 39 | Middle Aged |
| 25 | Adult |
| 24 | Peptidyl-Dipeptidase A |
| 23 | Prognosis |
| 22 | China |
| 21 | Risk Assessment |
| 20 | Angiotensin-Converting Enzyme Inhibitors |
| 19 | Renin-Angiotensin System |
| 18 | Retrospective Studies |
| 17 | Severity of Illness Index |
| 17 | Diabetes Mellitus |
| 16 | Aged, 80 and over |
| 15 | Angiotensin Receptor Antagonists |
| 14 | Hypertension |
| 13 | Hospitalization |
| 12 | Prevalence |
| 11 | Young Adult |
| 11 | Global Health |
| 11 | Coronavirus |
| 11 | Age Factors |
| 10 | Treatment Outcome |
| 10 | Incidence |
| 10 | Adolescent |
| 9 | Survival Analysis |
| 9 | Heart Failure |
| 9 | Heart Diseases |
| 9 | Biomarkers |
| 9 | Animals |
| 8 | United States |
| 8 | Tomography, X-Ray Computed |
| 8 | Intensive Care Units |
| 8 | Diabetes Complications |
| 8 | Clinical Laboratory Techniques |
| 8 | Child |
| 8 | Antiviral Agents |
| 7 | Receptors, Virus |
| 7 | Quarantine |
| 7 | Practice Guidelines as Topic |
| 7 | Cardiology |
| 6 | Sex Factors |
| 6 | Critical Illness |
| 6 | Antihypertensive Agents |
| 5 | United Kingdom |
| 5 | Neoplasms |
| 5 | Infection Control |
| 5 | Hydroxychloroquine |
| 5 | Hospital Mortality |
| 5 | Fever |
| 5 | Europe |
| 5 | Disease Outbreaks |
| 5 | Cough |
| 5 | Consensus |
| 5 | Chronic Disease |
| 5 | Cause of Death |
| 4 | Telemedicine |
| 4 | Societies, Medical |
| 4 | Signal Transduction |
| 4 | Sedentary Behavior |
| 4 | Respiratory Distress Syndrome, Adult |
| 4 | Respiration, Artificial |
| 4 | Renal Dialysis |
| 4 | Randomized Controlled Trials as Topic |
| 4 | Radiography, Thoracic |
| 4 | Pulmonary Disease, Chronic Obstructive |
| 4 | Personal Protective Equipment |
| 4 | Obesity |
| 4 | Myocarditis |
| 4 | Myocardial Infarction |
| 4 | Mineralocorticoid Receptor Antagonists |
| 4 | Lung |
| 4 | Lung Diseases |
| 4 | Inflammation |
| 4 | Hypoglycemic Agents |
| 4 | Diabetes Mellitus, Type 2 |
| 4 | Delivery of Health Care |
| 4 | Critical Care |
| 4 | Communicable Disease Control |
| 4 | Child, Preschool |
| 4 | Blood Glucose |
| 4 | Azithromycin |
| 3 | Time Factors |
| 3 | Spain |
| 3 | Socioeconomic Factors |
| 3 | Prospective Studies |
| 3 | Primary Prevention |
| 3 | Pregnancy |
| 3 | Myocardium |
| 3 | Mice |
| 3 | Logistic Models |
| 3 | Italy |
| 3 | Infant |
| 3 | Host Microbial Interactions |
| 3 | Health Personnel |
| 3 | Drug Combinations |
| 3 | Disease Susceptibility |
| 3 | Disease Progression |
| 3 | Disease Management |
| 3 | Diet |
| 3 | Cost of Illness |
| 3 | Cardiovascular System |
| 3 | Arrhythmias, Cardiac |
| 3 | Anti-Bacterial Agents |
| 3 | Angiotensin II Type 1 Receptor Blockers |
| 3 | Alanine |
| 3 | Aging |
| 3 | Adenosine Monophosphate |
| 2 | Troponin |
| 2 | Triage |
| 2 | Thromboembolism |
| 2 | Symptom Assessment |
| 2 | Survival Rate |
| 2 | Spike Glycoprotein, Coronavirus |
| 2 | Social Isolation |
| 2 | Severe Acute Respiratory Syndrome |
| 2 | Serine Endopeptidases |
| 2 | Ritonavir |
| 2 | Renal Insufficiency, Chronic |
| 2 | Registries |
| 2 | Recombinant Proteins |
| 2 | RNA, Viral |
| 2 | Public Health |
| 2 | Proportional Hazards Models |
| 2 | Population Surveillance |
| 2 | Percutaneous Coronary Intervention |
| 2 | Peptide Fragments |
| 2 | Patient Discharge |
| 2 | Odds Ratio |
| 2 | New York City |
| 2 | Mortality |
| 2 | Models, Statistical |
| 2 | Mexico |
| 2 | Lopinavir |
| 2 | Loneliness |
| 2 | Kidney Failure, Chronic |
| 2 | Kidney Diseases |
| 2 | Interleukin-6 |
| 2 | Inpatients |
| 2 | Infant, Newborn |
| 2 | Immunosuppressive Agents |
| 2 | Host-Pathogen Interactions |
| 2 | Heart |
| 2 | Heart Defects, Congenital |
| 2 | Follow-Up Studies |
| 2 | Fatigue |
| 2 | Extracorporeal Membrane Oxygenation |
| 2 | Exercise |
| 2 | Enzyme Inhibitors |
| 2 | Dyspnea |
| 2 | Drug-Related Side Effects and Adverse Reactions |
| 2 | Disinfection |
| 2 | Developing Countries |
| 2 | Databases, Factual |
| 2 | Cytokines |
| 2 | Cytokine Release Syndrome |
| 2 | Combined Modality Therapy |
| 2 | Cohort Studies |
| 2 | Clinical Protocols |
| 2 | Chloroquine |
| 2 | Cardiovascular Agents |
| 2 | Cardiomyopathies |
| 2 | Cardiologists |
| 2 | Body Mass Index |
| 2 | Asthma |
| 2 | Antimalarials |
| 2 | Angiotensins |
| 2 | Adrenal Cortex Hormones |
| 2 | Acute Kidney Injury |
| 2 | ADAM17 Protein |
| 1 | Washington |
| 1 | Vulnerable Populations |
| 1 | Vitamin D |
| 1 | Visual Field Tests |
| 1 | Virus Internalization |
| 1 | Virus Attachment |
| 1 | Viral Proteins |
| 1 | Viral Nonstructural Proteins |
| 1 | Vagus Nerve Stimulation |
| 1 | Urban Population |
| 1 | Up-Regulation |
| 1 | Turkey |
| 1 | Tuberculosis |
| 1 | Troponin T |
| 1 | Troponin I |
| 1 | Travel |
| 1 | Tertiary Care Centers |
| 1 | Takotsubo Cardiomyopathy |
| 1 | Sweden |
| 1 | Stroke |
| 1 | Statistics, Nonparametric |
| 1 | State Medicine |
| 1 | Specimen Handling |
| 1 | Somatostatin |
| 1 | Social Support |
| 1 | Social Distance |
| 1 | Single-Cell Analysis |
| 1 | Shock |
| 1 | Shock, Septic |
| 1 | Shock, Cardiogenic |
| 1 | Sequence Alignment |
| 1 | Self Efficacy |
| 1 | Secondary Prevention |
| 1 | SARS Virus |
| 1 | Rural Population |
| 1 | Risk |
| 1 | Risk Reduction Behavior |
| 1 | Risk Management |
| 1 | Reverse Transcriptase Polymerase Chain Reaction |
| 1 | Respiratory Insufficiency |
| 1 | Respiration Disorders |
| 1 | Residence Characteristics |
| 1 | Research Design |
| 1 | Republic of Korea |
| 1 | Renin |
| 1 | Remote Consultation |
| 1 | Regeneration |
| 1 | Reference Values |
| 1 | Recurrence |
| 1 | Receptors, Notch |
| 1 | Receptor, Angiotensin, Type 1 |
| 1 | Rats |
| 1 | Rats, Inbred Lew |
| 1 | Rare Diseases |
| 1 | Ramipril |
| 1 | Radiotherapy |
| 1 | ROC Curve |
| 1 | RNA Splicing |
| 1 | RNA Splice Sites |
| 1 | Public Policy |
| 1 | PubMed |
| 1 | Propensity Score |
| 1 | Professional Practice |
| 1 | Procedures and Techniques Utilization |
| 1 | Prenatal Diagnosis |
| 1 | Prenatal Care |
| 1 | Pregnancy, High-Risk |
| 1 | Pregnancy Complications |
| 1 | Pregnancy Complications, Infectious |
| 1 | Precision Medicine |
| 1 | Poverty |
| 1 | Poland |
| 1 | Platelet Aggregation Inhibitors |
| 1 | Pituitary Neoplasms |
| 1 | Pituitary Apoplexy |
| 1 | Physical Fitness |
| 1 | Phenotype |
| 1 | Peripheral Arterial Disease |
| 1 | Perioperative Care |
| 1 | Pericytes |
| 1 | Peptides, Cyclic |
| 1 | Patient Transfer |
| 1 | Patient Education as Topic |
| 1 | Patient Care |
| 1 | Patient Care Management |
| 1 | Patient Admission |
| 1 | Patient Acuity |
| 1 | Oxygen Inhalation Therapy |
| 1 | Oxidative Phosphorylation |
| 1 | Overweight |
| 1 | Outpatient Clinics, Hospital |
| 1 | Oral Hygiene |
| 1 | Octreotide |
| 1 | Observational Studies as Topic |
| 1 | Nucleic Acid Conformation |
| 1 | Non-Randomized Controlled Trials as Topic |
| 1 | Nomograms |
| 1 | New Orleans |
| 1 | Neurosurgical Procedures |
| 1 | Nephrology |
| 1 | Neovascularization, Physiologic |
| 1 | Natriuretic Peptide, Brain |
| 1 | Nasal Mucosa |
| 1 | Myocytes, Cardiac |
| 1 | Myocardial Ischemia |
| 1 | Mycobacterium tuberculosis |
| 1 | Myalgia |
| 1 | Mutation |
| 1 | Muscle, Skeletal |
| 1 | Muscle Development |
| 1 | Muscle Cells |
| 1 | Multiple Organ Failure |
| 1 | Multiple Chronic Conditions |
| 1 | Mucocutaneous Lymph Node Syndrome |
| 1 | Molecular Targeted Therapy |
| 1 | Minority Groups |
| 1 | Microtubule-Associated Proteins |
| 1 | MicroRNAs |
| 1 | Mice, Knockout |
| 1 | Mice, Inbred C57BL |
| 1 | Methylprednisolone |
| 1 | Metabolic Syndrome |
| 1 | Metabolic Diseases |
| 1 | Mental Health |
| 1 | Melatonin |
| 1 | Medicine, Chinese Traditional |
| 1 | Medication Therapy Management |
| 1 | Medical Oncology |
| 1 | Macaca mulatta |
| 1 | Lymphopenia |
| 1 | Lymphocyte Count |
| 1 | Lymphocyte Activation |
| 1 | Lung Injury |
| 1 | Life Style |
| 1 | Length of Stay |
| 1 | Laboratories |
| 1 | Kaplan-Meier Estimate |
| 1 | Ischemia |
| 1 | Intra-Aortic Balloon Pumping |
| 1 | International Cooperation |
| 1 | Interferons |
| 1 | Interferon Type I |
| 1 | Insulin |
| 1 | Insulin Resistance |
| 1 | Influenza, Human |
| 1 | Infectious Disease Transmission, Professional-to-Patient |
| 1 | Infectious Disease Transmission, Patient-to-Professional |
| 1 | India |
| 1 | Incretins |
| 1 | Immunologic Factors |
| 1 | Immunocompromised Host |
| 1 | Immunization, Passive |
| 1 | Immunity |
| 1 | Immunity, Innate |
| 1 | Hypolipidemic Agents |
| 1 | Hyperlipoproteinemia Type II |
| 1 | Hyperlipidemias |
| 1 | Hydroxymethylglutaryl-CoA Reductase Inhibitors |
| 1 | Human Growth Hormone |
| 1 | Human Activities |
| 1 | Hospitals |
| 1 | Hospitals, University |
| 1 | Hormone Replacement Therapy |
| 1 | Heart-Assist Devices |
| 1 | Heart Injuries |
| 1 | Heart Arrest |
| 1 | Healthy Lifestyle |
| 1 | Healthcare Disparities |
| 1 | Health Status |
| 1 | Health Status Indicators |
| 1 | Health Status Disparities |
| 1 | Health Services Accessibility |
| 1 | Health Care Rationing |
| 1 | Hand Disinfection |
| 1 | HIV Infections |
| 1 | Guidelines as Topic |
| 1 | Goblet Cells |
| 1 | Glycolysis |
| 1 | Glucocorticoids |
| 1 | Glucagon-Like Peptide-1 Receptor |
| 1 | Global Burden of Disease |
| 1 | Geriatrics |
| 1 | Georgia |
| 1 | Genome, Viral |
| 1 | Genetic Predisposition to Disease |
| 1 | Genetic Counseling |
| 1 | Gene Expression |
| 1 | Gene Expression Regulation |
| 1 | Gene Expression Profiling |
| 1 | Furin |
| 1 | France |
| 1 | Forced Expiratory Volume |
| 1 | Food Supply |
| 1 | Feeding Behavior |
| 1 | Evidence-Based Medicine |
| 1 | Ethnic Groups |
| 1 | Epigenesis, Genetic |
| 1 | Epidemiological Monitoring |
| 1 | Epidemics |
| 1 | Enterocytes |
| 1 | Energy Metabolism |
| 1 | Energy Intake |
| 1 | Educational Status |
| 1 | Economics |
| 1 | Economic Recession |
| 1 | Echocardiography |
| 1 | Early Diagnosis |
| 1 | Dyslipidemias |
| 1 | Drugs, Chinese Herbal |
| 1 | Drug Therapy, Combination |
| 1 | Drug Interactions |
| 1 | Drug Discovery |
| 1 | Dopamine Agonists |
| 1 | Dipeptidyl Peptidase 4 |
| 1 | Diagnostic Techniques, Cardiovascular |
| 1 | Diagnostic Errors |
| 1 | Diabetic Cardiomyopathies |
| 1 | Dermatitis, Atopic |
| 1 | Databases, Genetic |
| 1 | Cross Infection |
| 1 | Creatinine |
| 1 | Continental Population Groups |
| 1 | Consciousness Disorders |
| 1 | Confounding Factors, Epidemiologic |
| 1 | Confined Spaces |
| 1 | Community Networks |
| 1 | Commerce |
| 1 | Clinical Trials, Phase III as Topic |
| 1 | Clinical Deterioration |
| 1 | Clinical Decision-Making |
| 1 | Civil Defense |
| 1 | Cities |
| 1 | Chi-Square Distribution |
| 1 | Channelopathies |
| 1 | Cerebrovascular Disorders |
| 1 | Cells, Cultured |
| 1 | Cell Line |
| 1 | Caspases, Initiator |
| 1 | Caspase 1 |
| 1 | Case-Control Studies |
| 1 | Cardiovascular Surgical Procedures |
| 1 | Cardiovascular Physiological Phenomena |
| 1 | Cardiotoxicity |
| 1 | Cardiotonic Agents |
| 1 | Cardiology Service, Hospital |
| 1 | Cardiac Surgical Procedures |
| 1 | Cardiac Rehabilitation |
| 1 | Cardiac Catheterization |
| 1 | Canada |
| 1 | California |
| 1 | Cabergoline |
| 1 | CD8-Positive T-Lymphocytes |
| 1 | CD4-Positive T-Lymphocytes |
| 1 | CD4 Lymphocyte Count |
| 1 | C-Reactive Protein |
| 1 | Brazil |
| 1 | Blood Glucose Self-Monitoring |
| 1 | Blood Coagulation |
| 1 | Blood Chemical Analysis |
| 1 | Blood Cell Count |
| 1 | Biological Specimen Banks |
| 1 | Basic Reproduction Number |
| 1 | Base Sequence |
| 1 | Autophagy |
| 1 | Autophagosomes |
| 1 | Australia |
| 1 | Atrial Fibrillation |
| 1 | Asymptomatic Diseases |
| 1 | Asian Continental Ancestry Group |
| 1 | Argentina |
| 1 | Antioxidants |
| 1 | Antineoplastic Agents |
| 1 | Antineoplastic Agents, Hormonal |
| 1 | Antibodies, Monoclonal, Humanized |
| 1 | Anti-Inflammatory Agents |
| 1 | Anti-Infective Agents |
| 1 | Anti-Arrhythmia Agents |
| 1 | Angiotensin II |
| 1 | Angiotensin I |
| 1 | Anesthetics |
| 1 | Anesthesiology |
| 1 | Ambulatory Care |
| 1 | Alveolar Epithelial Cells |
| 1 | Algorithms |
| 1 | Airway Management |
| 1 | Air Pollution |
| 1 | Air Conditioning |
| 1 | Age Distribution |
| 1 | Aftercare |
| 1 | African Continental Ancestry Group |
| 1 | Advisory Committees |
| 1 | Adipose Tissue |
| 1 | Adenoma |
| 1 | Acute Disease |
| 1 | Acute Coronary Syndrome |
| 1 | 3' Untranslated Regions |
